Newsroom | 4180 results

MINNEAPOLIS--(BUSINESS WIRE)--A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that a donor search prognosis-based strategy helps physicians move patients with blood cancers and other blood diseases to hematopoietic cell transplant (HCT) faster, resulting in similar transplant success regardless of likelihood of finding a matched unrelated donor (MUD). Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marr...

WATERTOWN, Mass.--(BUSINESS WIRE)--Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, today announced that biotech pioneer John Maraganore, Ph.D. has joined the company as a strategic adviser. Dr. Maraganore will advise Corner on corporate strategy, business development, and the advancement of its dendritic cell-initiated T cell engineering (DCITE) platform with a goal of developing its pipeline of novel immunotherapi...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announces multiple strategic technology partnerships to advance the Cell Q™, the first fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. Cellares is unveiling these partnerships ahead of the 10th Annual CAR-TCR Summit, where it will, for the first time, present drug product release da...

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the publication of Phase 1/2a clinical trial results in a paper titled "Safety and Tolerability of RPE Stem Cell-derived RPE Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes" in the journal Cell Stem C...

MINNETONKA, Minn.--(BUSINESS WIRE)--Nu-Tek BioSciences, the market leader in plant-based peptones and yeast extracts for the biopharmaceutical industry, has been awarded the Bronze designation 2025 by EcoVadis for the second year. This distinction places Nu-Tek among the top 35% of companies evaluated by EcoVadis and underscores its ongoing commitment to environmental stewardship and responsible business practices. EcoVadis assesses companies across key sustainability criteria, including enviro...

MINNEAPOLIS--(BUSINESS WIRE)--NMDP℠, the organization that operates the national registry of unrelated blood stem cell donors and cord blood units, applauds Representatives Chris Smith (R-NJ), Doris O. Matsui (D-CA), Gus Bilirakis (R-FL), Chellie Pingree (D-ME), Claudia Tenney (R-NY) and Kweisi Mfume (D-MD) for the introduction of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025—a critical bipartisan bill that helps thousands of patients annually who are battling li...

MACCLESFIELD, England--(BUSINESS WIRE)--Pencil Biosciences, a biotech company pioneering a new class of gene editor, today announced the appointment of Jonathan Thon, PhD, as the new Chair of its Board of Directors. The company's novel platform, which offers "break-free editing” and versatile, unrestricted gene targeting, is designed to overcome limitations in access and off-target modifications of existing technologies to enable the next generation of gene editing therapies. “Jonathan brings a...

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of INTENT Biologics, a new independent biotechnology company focused exclusively on developing first-in-class exosome therapies for Inflammation & Immunology (I&I). INTENT Biologics launches with exclusive, perpetual worldwide rights to RION’s Purified Exosome Product (PEP™) biologic platform in I&I and will advance PE...

WATERTOWN, Mass.--(BUSINESS WIRE)--Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, today published research in mBio, a leading microbiology journal, showing that a novel technology to generate T cells in vivo significantly outperforms standard influenza vaccine adjuvants. The study shows that the technology elicits a broadly acting immune response that targets all strains of influenza present in the commercial quad...

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- PHCホールディングス（本社：東京都千代田区）傘下のPHC株式会社 バイオメディカ事業部（本社：東京都千代田区、代表取締役社長：中村 伸朗、以下「バイオメディカ事業部」）は、このたび、当社のライブセル代謝分析装置「LiCellMo™（リセルモ）」（＊１）が、米国の科学技術メディアR&D World誌が主催する「2025 R&D100アワード(2025 R&D 100 Awards)」を受賞(＊２)しましたので、お知らせいたします。 「LiCellMo」は、研究用途として2024年9月に日本国内で発売し、その後10月には米国、英国、EU諸国、中国の他、アジアの一部地域でも提供を開始しました。本製品は、細胞の代謝経路（＊３）を連続的なデータとして測定し、これまで観察できなかった細胞の状態の経時変化を可視化することができます。これにより、研究における新たな知見の獲得や治療法の進展へ寄与します。 本製品は、細胞代謝メカニズムの解明や、細胞医薬品の製造プロセス開発において重要な細胞培養の再現性および品質...